BRAF inhibitor therapy in HCL

Publication date: Available online 20 October 2015 Source:Best Practice & Research Clinical Haematology Author(s): Sascha Dietrich, Thorsten Zenz Targeted treatment approaches are transforming the therapeutic landscape of cancer care. The discovery of the BRAF V600E mutation in most cases of classical hairy cell leukemia opens up unique opportunities for tumor specific treatment of HCL targeting the MEK/ERK signaling pathway. The discovery and biological implications of BRAF V600E in HCL are summarized to form a basis for our current understanding of the potential for clinical exploitation. There is overwhelming clinical evidence for activity of inhibitors of BRAF in the disease. The review will review current trial activity as well as discuss novel trial concepts exploiting targeted treatment focusing on BRAF inhibition in HCL.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research